Details

Autor(en) / Beteiligte

• Chandasana, Hardik
• Thapar, Mita
• Hayes, Siobhan
• Baker, Mark
• Gibb, Diana M.
• Turkova, Anna
• Ford, Deborah
• Ruel, Theodore
• Wiznia, Andrew
• Fairlie, Lee
• Bwakura-Dangarembizi, Mutsa
• Mujuru, Hilda
• Alvero, Carmelita
• Farhad, Mona
• Hazra, Rohan
• Townley, Ellen
• Buchanan, Ann
• Bollen, Pauline
• Waalewijn, Hylke
• Colbers, Angela
• Burger, David
• Acosta, Edward P.
• Singh, Rajendra

Titel

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents

Ist Teil von

• Clinical pharmacokinetics, 2023-10, Vol.62 (10), p.1445-1459

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Background and Objective HIV treatment options remain limited in children. Dolutegravir is a potent and well-tolerated, once-daily HIV-1 integrase inhibitor recommended for HIV-1 infection in both adults and children down to 4 weeks of age. To support pediatric dosing of dolutegravir in children, we used a population pharmacokinetic model with dolutegravir data from the P1093 and ODYSSEY clinical trials. The relationship between dolutegravir exposure and selected safety endpoints was also evaluated. Methods A population pharmacokinetic model was developed with data from P1093 and ODYSSEY to characterize the pharmacokinetics and associated variability and to evaluate the impact of pharmacokinetic covariates. The final population pharmacokinetic model simulated exposures across weight bands, doses, and formulations that were compared with established adult reference data. Exploratory exposure–safety analyses evaluated the relationship between dolutegravir pharmacokinetic parameters and selected clinical laboratory parameters and adverse events. Results A total of N = 239 participants were included, baseline age ranged from 0.1 to 17.5 years, weight ranged from 3.9 to 91 kg, 50% were male, and 80% were black. The final population pharmacokinetic model was a one-compartment model with first-order absorption and elimination, enabling predictions of dolutegravir concentrations in the pediatric population across weight bands and doses/formulations. The predicted geometric mean trough concentration was comparable to the adult value following a 50-mg daily dose of dolutegravir for all weight bands at recommended doses. Body weight, age, and formulation were significant predictors of dolutegravir pharmacokinetics in pediatrics. Additionally, during an exploratory exposure–safety analysis, no correlation was found between dolutegravir exposure and selected safety endpoints or adverse events. Conclusions The dolutegravir dosing in children ≥ 4 weeks of age on an age/weight-band basis provides comparable exposures to those historically observed in adults. Observed pharmacokinetic variability was higher in this pediatric population and no additional safety concerns were observed. These results support the weight-banded dosing of dolutegravir in pediatric participants currently recommended by the World Health Organization.